DVHGF OTC
Credit Risk of going bust: higher than 56% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
Total debt $100K against a stock market value of $16.3M.
Distance to default 4.56 (Merton model): prices to 2026-10-21, balance sheet 2026-04-30, debt counted $58K (short-term plus half of long-term), stock volatility 111.6%; Altman Z'' -19.08. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Québec, QC G5V 4T1
CA
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
